In real-world settings, adding pertuzumab to neoadjuvant therapy significantly improves pCR rates in early-stage HER2+ breast cancer, aligning with RCT evidence. These findings support the broader adoption of dual HER2 blockade and highlight the need for further prospective real-world studies to refine treatment strategies for specific patient subgroups.
Building similarity graph...
Analyzing shared references across papers
Loading...
Matsas et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69af952b70916d39fea4c80e — DOI: https://doi.org/10.31557/apjcp.2026.27.3.813
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Silvio Matsas
Julita Zembala
Anderson Ruiz Simões
Asian Pacific Journal of Cancer Prevention
University of North Carolina at Chapel Hill
The University of Texas Southwestern Medical Center
UNC Lineberger Comprehensive Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...